Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to observe conduction disturbance, daily activity level, heart rates, oxygen saturation in patients who underwent Transcatheter Aortic Valve Replacement (TAVR) and to evaluate the utility of the HUAWEI Watch (HUAWEI Technologies Co., Ltd., Shenzhen, China) for the potential early warning sign of changes in multiple biometric parameters including heart rate, rhythm, oxygen saturation, activity, and sleep in patients following TAVR. This will be evaluated in the context of a recently implemented early discharge protocol.
This is a prospective observational cohort study including patients undergoing TAVR procedure in Second Affiliated Hospital of Zhejiang University, School of Medicine. HUAWEI Watch will be assigned to patients within 24 hours before TAVR. HUAWEI Watch GT series can continuously monitor and record multiple biometric parameters heart rate, step counts, sleep cycles and can detect and record the pulse oxygen saturation, as well as analyze QRS complexes and P waves after triggering. The patients will be followed in outpatient clinic visits at 1, 6, 12, 24, and 36 months after TAVR and will commence monitoring with the HUAWEI Watch protocol at least 1 day before the scheduled TAVR procedure to allow familiarity with the device. Patients will be required to activate SMART watch readings (including pulse oxygen saturation and ECG) at least once prior to TAVR and twice per day in the week following TAVR discharge (morning and late afternoon/early evening), at least two days a week for the subsequent month after TAVR discharge and at least once weekly for the remainder of the study. Patients will also be required to activate SMART watch readings at times of any cardiovascular symptoms including dyspnea, chest pain, palpitations, dizziness or presyncope. The health data recorded by HUAWEI Watch will be transmitted to HUAWEI phone application. The Heart Health App (developed by Second Affiliated Hospital, School of Medicine, Zhejiang University) will receive, process and store the data, and transfer it to remote database after approval by patients. A designated heart team member would access the data via a cloud database, contact the patient further investigation or management was deemed necessary.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SMART watch | Medical records from patients aged 18 years or older undergoing Transcatheter Aortic Valve Replacement |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HUAWEI watch | Device | HUAWEI Watch will be assigned to patients within 24 hours before TAVR. HUAWEI Watch GT series can continuously monitor and record multiple biometric parameters heart rate, step counts, sleep cycles and can detect and record the pulse oxygen saturation, as well as analyze QRS complexes and P waves after triggering. |
| Measure | Description | Time Frame |
|---|---|---|
| Composite of Death and Rehospitalization | Kaplan-Meier Estimate of Death or Rehospitalization from date of discharge, compared to a historical control. Rehospitalization is defined as any hospitalization related to the procedure, the valve or heart failure. | 30-day |
| Days Alive and Out of Hospital (DAOH) | Kaplan-Meier Estimate of Days Alive and Out of Hospital (DAOH) from date of discharge, compared to a historical control. | 30-day |
| Measure | Description | Time Frame |
|---|---|---|
| Composite of Death and Rehospitalization | Kaplan-Meier Estimate of Death or Rehospitalization from date of discharge, compared to a historical control. Rehospitalization is defined as any hospitalization related to the procedure, the valve or heart failure. | 1-year, 2-year, and 3-year at follow-up |
| Days Alive and Out of Hospital (DAOH) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients aged 18 years or older who undergoing Transcatheter Aortic Valve Replacement were the initial target population.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jiaqi Fan, MD | Contact | +86-15267029492 | fanjiaqi@zju.edu.cn | |
| Xianbao Liu, MD, PhD | Contact | +86-13857173887 | liuxb2009@hotmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Jian-an Wang, MD, PhD | Second Affiliated Hospital, School of Medicine, Zhejiang University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | Hangzhou | Zhejiang | 310000 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39028996 | Derived | Fan J, Dai H, Guo Y, Xu J, Wang L, Jiang J, Lin X, Li C, Zhou D, Li H, Liu X, Wang J. Smartwatch-Detected Arrhythmias in Patients After Transcatheter Aortic Valve Replacement (TAVR): Analysis of the SMART TAVR Trial. J Med Internet Res. 2024 Jul 19;26:e41843. doi: 10.2196/41843. | |
| 38088154 | Derived | Fan J, Liu Q, Dai H, Zhou D, Guo Y, Xu J, Wang L, Hu P, Jiang J, Lin X, Li C, Liu X, Wang J. Daily Physical Activity Measured by Wearable Smartwatch for Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the SMART TAVR Study. Circ Cardiovasc Qual Outcomes. 2024 Jan;17(1):e010066. doi: 10.1161/CIRCOUTCOMES.123.010066. Epub 2023 Dec 13. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Kaplan-Meier Estimate of Days Alive and Out of Hospital (DAOH) from date of discharge, compared to a historical control. |
| 1-year, 2-year, and 3-year at follow-up |
| Incidence of pacemaker implantation | Incidence of pacemaker implantation. | 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Time of pacemaker implantation | Time of pacemaker implantation will record the time point of the pacemaker implantation. | 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| New York Heart Association (NYHA) Functional Class | NYHA provides a way of classifying the extent of heart failure. New York Heart Association (NYHA) is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I-IV, with the NYHA I as no limitation and NYHA IV unable to carry on any physical activity. | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Kansas City Cardiomyopathy Questionnaire (KCCQ) | The Kansas City Cardiomyopathy Questionnaire (KCCQ) are on a range of 0-100, in which 100 reflects the best health status and 0 reflects the worst health status. | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Hemoglobin | Laboratory examination include hemoglobin, pro-BNP, albumin, creatinine. The unit of Hemoglobin is mg/dL. | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Pro-BNP | Laboratory examination include hemoglobin, pro-BNP, albumin, creatinine. The unit of Pro-BNP is pg/mL. | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Albumin | Laboratory examination include hemoglobin, pro-BNP, albumin, creatinine. The unit of Albumin is g/L. | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Creatinine | Laboratory examination include hemoglobin, pro-BNP, albumin, creatinine. The unit of Creatinine of umol/L. | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Echocardiography examinations | Echocardiography examinations include valvular mean gradient, paravalvular leakage, valvular regurgitation, left ventricular ejection fraction, left ventricular diameter, left atrial size, and pulmonary arterial systolic pressure. | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Computed tomography examinations | computed tomography examinations include CT assessment parameters, like annular area, perimeter, diameter, SOV, and Coronary height. | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Rates of onset of conduction disturbance recorded by Watch | Rates of onset of conduction disturbance recorded by Watch | 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Time of onset of conduction disturbance recorded by Watch | Time of onset of conduction disturbance will record the time point of the onset of conduction disturbance. | 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Rates of onset of new atrial fibrillation or ventricular arrhythmia recorded by Watch | Rates of onset of new atrial fibrillation or ventricular arrhythmia recorded by Watch. | 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Time of onset of new atrial fibrillation or ventricular arrhythmia recorded by Watch | Time of new atrial fibrillation or ventricular arrhythmia will record the time point of the onset of new atrial fibrillation or ventricular arrhythmia. | 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Average daily step counts recorded by Watch | Average daily step counts recorded by Watch is one assessment of daily activity. | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Moderate to vigorous physical activity time recorded by Watch | Moderate to vigorous physical activity time recorded by Watch is one assessment of daily activity. | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| SpO2 detected by Watch | SpO2 detected by Watch | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Heart rate assessment recorded by Watch | Heart rate assessment includes average heart rate, resting heart rate, and premature beats ratio recorded by Watch | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Assessment of sleep reported by Watch | Assessment of sleep reported by Watch | baseline, 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Rates of cardiac event identified by the watch leading to change of therapy or intervention | Rates of cardiac event identified by the watch leading to change of therapy or intervention | 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| Time of cardiac event identified by the watch leading to change of therapy or intervention | Time of cardiac event identified by the watch leading to change of therapy or intervention | 30-day, 6-month, 1-year, 2-year, and 3-year at follow-up |
| 35347997 | Derived | Liu X, Fan J, Guo Y, Dai H, Xu J, Wang L, Hu P, Lin X, Li C, Zhou D, Li H, Wang J. Wearable Smartwatch Facilitated Remote Health Management for Patients Undergoing Transcatheter Aortic Valve Replacement. J Am Heart Assoc. 2022 Apr 5;11(7):e023219. doi: 10.1161/JAHA.121.023219. Epub 2022 Mar 29. |
| ID | Term |
|---|---|
| D001024 | Aortic Valve Stenosis |
| D006349 | Heart Valve Diseases |
| ID | Term |
|---|---|
| D000082862 | Aortic Valve Disease |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014694 | Ventricular Outflow Obstruction |
Not provided
Not provided